Takeda Acquires US Biologics Manufacturing Facility

Article

Takeda Pharmaceuticals announced the acquisition of a biopharmaceuticals manufacturing plant in Minnesota.

Takeda Pharmaceutical Company Limited announced the acquisition of a Brooklyn Park, Minnesota-based biologics manufacturing facility from Baxalta Inc in a Jan. 6, 2016 press announcement.

Takeda is a Japan-based pharmaceutical company focused on research and development. It is the largest pharmaceutical company in Japan.

According to the company, Takeda intends to use the facility primarily for the manufacture of Entyvio (vedolizumab) and other biologic products. FDA approved Entyvio in May 2014 for the treatment of ulcerative colitis and moderate-to-severe Crohn’s disease.

Terms of the transaction were not disclosed.

Source: Takeda Pharmaceutical Company

Recent Videos
Jens Schmidt, associate director MSAT at Lonza
Behind the Headlines episode 8
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Roger Viney, PhD, chief commercial officer for ICE Pharma
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Related Content
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

Pharmapack Reports on Key Trends for 2025

Feliza Mirasol
January 16th 2025
Article

Pharmapack identifies biologic approvals, drug delivery advancements, GLP-1 generics, and the return of funding flow as drivers for a record year in 2025.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept | Image Credit: © Dilok – © Dilok - stock.adobe.com

Lonza and Iconovo Team Up on Intranasal Biologic Candidate

Feliza Mirasol
January 15th 2025
Article

Lonza will work with Iconovo to develop spray-dried formulations for an intranasally delivered biologic using a reformulated biologic drug candidate for obesity.

Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain

Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain

Jill Murphy
November 14th 2023
Podcast

In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.

Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept. | Image Credit: © Dilok - stock.adobe.com

Scribe Reports Milestone for In Vivo Program Collaboration with Sanofi

Patrick Lavery
January 14th 2025
Article

Although specifics about the milestone were not immediately provided, Scribe is eligible to receive more than $1.2 billion for certain research, development, regulatory, and commercial benchmarks.

Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept. | Image Credit: © Dilok - stock.adobe.com

Telix Enters Agreement with ImaginAb to Purchase Next-Gen Therapeutic Candidates

Patrick Lavery
Published: January 13th 2025 | Updated: January 13th 2025
Article

The transaction adds a pipeline of early-stage drug candidates against high-value targets to Telix’s portfolio, along with other novel targets currently in the discovery stage.